title: Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction.
abstract: Extracellular matrix (ECM) remodeling is a critical aspect of cardiac remodeling following myocardial infarction. Tissue inhibitors of metalloproteinases (TIMPs) are physiological inhibitors of matrix metalloproteinases (MMPs) that degrade the ECM proteins. TIMP3 is highly expressed in the heart, and is markedly downregulated in patients with ischemic cardiomyopathy. We therefore examined the time- and region-dependent role of TIMP3 in the cardiac response to myocardial infarction (MI). TIMP3(-/-) and wild-type (WT) mice were subjected to MI by ligation of the left anterior descending artery. TIMP3(-/-)-MI mice exhibited a significantly compromised rate of survival compared with WT-MI mice, primarily due to increased left ventricular (LV) rupture, greater infarct expansion, exacerbated LV dilation, and greater systolic and diastolic dysfunction. Second harmonic generation imaging of unfixed and unstained hearts revealed greater collagen disarray and reduced density in the TIMP3(-/-) infarct myocardium compared with the WT group. Gelatinolytic and collagenolytic activities increased in TIMP3(-/-) compared with WT hearts at 1 day post-MI but not at 3 days or 1 wk post-MI. Neutrophil infiltration and inflammatory MMPs were significantly increased in the infarct and peri-infarct regions of TIMP3(-/-)-MI hearts. Treatment of TIMP3(-/-) mice with a broad-spectrum MMP inhibitor (PD-166793) for 2 days before and 2 days after MI markedly improved post-MI infarct expansion, LV rupture incident, LV dilation, and systolic dysfunction in these mice up to 1 wk post-MI. Our data demonstrate that the initial rise in proteolytic activities early post-MI is a triggering factor for subsequent LV adverse remodeling, LV rupture, and dilated cardiomyopathy. Hence, timing of treatments to improve cardiac response to MI may be critical in producing favorable outcome.
authors.affiliation: Department of Physiology, University of Alberta, Edmonton, Alberta.
authors.forename: Vijay
authors.initials: V
authors.lastname: Kandalam
authors.forename: Ratnadeep
authors.initials: R
authors.lastname: Basu
authors.forename: Thomas
authors.initials: T
authors.lastname: Abraham
authors.forename: Xiuhua
authors.initials: X
authors.lastname: Wang
authors.forename: Ahmed
authors.initials: A
authors.lastname: Awad
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Gary D
authors.initials: GD
authors.lastname: Lopaschuk
authors.forename: Nobuyo
authors.initials: N
authors.lastname: Maeda
authors.forename: Gavin Y
authors.initials: GY
authors.lastname: Oudit
authors.forename: Zamaneh
authors.initials: Z
authors.lastname: Kassiri
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000502:physiology*; D003971:Diastole / Q000502:physiology; D004195:Disease Models, Animal; D006341:Heart Rupture / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009203:Myocardial Infarction / Q000378:metabolism*; D013599:Systole / Q000502:physiology; D013997:Time Factors; D019714:Tissue Inhibitor of Metalloproteinases / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D018487:Ventricular Dysfunction, Left / Q000378:metabolism; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases